For the second quarter of 2011, the company has generated net income of $2.73bn, compared to $2.44bn for the same period in the prior year.
Net sales were $28.94bn for the six months ended 30 June 2011, compared to $23.85bn for the same period in 2010.
Net income was $5.55bn for the six months of 2011, compared to $5.39bn for the same period in last year.
Novartis CEO Joseph Jimenez said they achieved sales growth of 19% in constant currencies and margin improvement of 0.4% points in US dollars.
"We further demonstrated the success of our R&D strategy with four major approvals and two filings in the second quarter," Jimenez said.